Hans van Houte is CFO at Nurix Therapeutics, Inc. (NRIX). They have made 21 open-market trades across 1 company since 2021, most recently 2026-08-04.
CIK 0001817217
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 21 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NRIX | 40,166 | $979K |
Shares reported on the most recent Form 4, priced at the 2026-08-04 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NRIX | SELL · 10b5-1 | 2026-08-04 | 2026-08-04 | $24.36 | $116K | +6.8% | -0.1% | — |
| NRIX | SELL | 2026-07-30 | 2026-07-30 | $23.38 | $67K | +10.5% | +9.7% | — |
| NRIX | SELL · 10b5-1 | 2026-05-05 | 2026-05-05 | $16.60 | $233K | -5.1% | -8.7% | +38.9% |
| NRIX | SELL | 2026-04-30 | 2026-04-30 | $16.65 | $40K | -3.8% | +4.8% | +42.2% |
| NRIX | SELL | 2026-01-30 | 2026-01-30 | $16.60 | $61K | -2.5% | -4.3% | +1.1% |
| NRIX | SELL · 10b5-1 | 2025-11-03 | 2025-11-03 | $12.56 | $158K | +1.1% | +36.8% | +38.9% |
| NRIX | SELL | 2025-10-30 | 2025-10-30 | $12.80 | $40K | +2.0% | +34.1% | +41.7% |
| NRIX | SELL · 10b5-1 | 2025-08-01 | 2025-08-01 | $11.03 | $119K | -4.7% | -17.9% | +15.2% |
| NRIX | SELL | 2025-07-30 | 2025-07-30 | $12.01 | $103K | -16.5% | -19.1% | +3.0% |
| NRIX | SELL · 10b5-1 | 2025-05-02 | 2025-05-02 | $11.33 | $140K | -13.4% | +9.8% | +1.8% |
| NRIX | SELL | 2025-04-30 | 2025-04-30 | $11.50 | $28K | -10.8% | -6.8% | +4.2% |
| NRIX | SELL · 10b5-1 | 2025-03-03 | 2025-03-03 | $14.49 | $84K | -5.1% | -18.1% | -12.7% |
| NRIX | SELL | 2025-01-30 | 2025-01-30 | $19.83 | $106K | -14.6% | -29.2% | -42.5% |
| NRIX | SELL · 10b5-1 | 2024-11-01 | 2024-11-01 | $24.28 | $172K | +10.9% | -12.2% | -18.3% |
| NRIX | SELL | 2024-10-30 | 2024-10-30 | $24.31 | $115K | +17.2% | -8.0% | -18.6% |
| NRIX | SELL · 10b5-1 | 2024-08-26 | 2024-08-26 | $25.22 | $504K | -8.0% | -7.2% | -13.9% |
| NRIX | SELL · 10b5-1 | 2024-08-01 | 2024-08-01 | $21.44 | $147K | +7.5% | +24.1% | +20.2% |
| NRIX | SELL | 2024-07-30 | 2024-07-30 | $20.67 | $103K | -3.7% | +15.6% | +22.3% |
| NRIX | SELL · 10b5-1 | 2024-06-20 | 2024-06-20 | $20.01 | $800K | -10.4% | +4.6% | +17.1% |
| NRIX | SELL · 10b5-1 | 2024-05-02 | 2024-05-02 | $12.83 | $45K | +13.7% | +22.1% | +66.4% |
| NRIX | SELL | 2024-04-30 | 2024-04-30 | $12.04 | $17K | +11.8% | +29.0% | +75.9% |
| NRIX | SELL · 10b5-1 | 2024-02-16 | 2024-02-16 | $10.02 | $137K | +29.7% | +34.9% | +61.8% |
| NRIX | SELL | 2024-01-30 | 2024-01-30 | $7.99 | $13K | +11.0% | +55.0% | +56.5% |
| NRIX | SELL · 10b5-1 | 2023-12-20 | 2023-12-21 | $10.00 | $35K | +5.8% | -14.5% | +42.6% |
| NRIX | SELL · 10b5-1 | 2023-12-19 | 2023-12-20 | $10.00 | $109K | -5.0% | -19.6% | +25.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.